A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer

European Journal of Cancer

Volumn 41, Issue 11, 2005, Pages 1547-1550

  Baka, S ^a   Ranson, M ^a   Lorigan, P ^b   Danson, S ^a   Linton, K ^a   Hoogendam, I ^c   Mettinger, K ^c   Thatcher, N ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b WESTON PARK HOSPITAL   (United Kingdom)

^c NDDO Representative ^*  (United Kingdom)

Author keywords

Non small cell lung cancer; RFS2000; Rubitecan; Topoisomerase I inhibitor

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; RUBITECAN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; FREQUENCY ANALYSIS; GRANULOCYTOPENIA; HUMAN; LETHARGY; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SAMPLE SIZE; SURVIVAL TIME; THROMBOCYTOPENIA; TIME SERIES ANALYSIS; TREATMENT OUTCOME; TUMOR GROWTH;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS;

EID: 22144481982     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2005.03.009     Document Type: Article

References (22)

1. R. Joss, F. Cavali, and A. Goldhirsch New agents in non small-cell lung cancer Cancer Treat Rev 11 1979 205 236
2. M. Cohen, N. Perevodchikova, and F. Muggia Single agent chemotherapy of lung cancer Lung cancer: Progress in therapeutic research 1979 Raven Press New York
3. H. Hans, and M. Roeth Lung cancer H. Pinedo D. Longo B. Chabner Cancer chemotherapy and biological response modifiers, Annual 12 1991 Elsevier Science Publishers B.V. 449 459
4. H. Choy, S. Kim, and H. Pyo Topoisomerase I inhibitors in the combined modality therapy of lung cancer Clin Lung Cancer 2 Suppl. 2 2001 S34 S40
5. S. White, S. Cheeseman, and N. Thatcher Phase II study of oral topotecan in advanced non-small cell lung cancer Clin Cancer Res 6 2000 868 873
6. J. Braybrooke, M. Ranson, and C. Manegold Phase II study of mesylate (DX-8951F) as first line therapy for advanced non-small cell lung cancer Lung Cancer 41 2003 215 219
7. M. Wall, M. Wani, and C. Cook Plant antitumor agents. I. The isolation and structure of camptothecin a novel alkaloidal leukaemia and tumour inhibitor from Camptotheca acuminata J Am Chem Soc 88 1996 3888 3890
8. M. Wani, A. Nickolas, and M. Wall Plant antitumor agents 23 synthesis and antileukemic activity of camptothecin analogues J Med Chem 29 1986 2358 2363
9. Hinz, H. Harris, and N. Natelson Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20 (S0-camptothecin to 9-amino-20 (S) in camptothecin humans, dogs and mice Cancer Res 54 1994 3096 3100
10. P. Pantazis Preclinical studies of water-insoluble camptothecin congeners: cytotoxicity, development of resistance, and combination treatments Clin Cancer Res 1 1995 1235 1244
11. C. Verschraegen, E. Natelson, and B. Giovanella A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor Anticancer Drug 9 1998 36 44
12. P. Schöffski, A. Herr, and J. Vermorken Clinical phase II study and pharmacological evaluation of rubitecan in non-pre-treated patients with metastatic colorectal cancer - significant effect of food intake on the bioavailability of the oral camptothecin analogue Eur J Cancer 38 2002 807 813
13. M. Konstadoulakis, P. Antonakis, and P. Tsibloulis A phase II study of 9-nitrocamptothecin in patients with advanced pancreatic adenocarcinoma Cancer Chemother Pharmacol 48 2001 417 420
14. E. Raymond, M. Campone, and R. Stupp Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitrocamptothecin) administered orally 5 days a week in patients with glioblastoma multiforme Eur J Cancer 38 2002 1348 1350
15. S. Patel, J. Beach, and N. Papadopoulos Results of a 2-arm phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas Cancer 97 2005 2848 2852
16. A. Ellerhorst, A. Bedikian, and T. Smith Phase II trial of 9-nitrocamptothecin (RFS2000) for patients with metastatic cutaneous or uveal melanoma Anticancer Drug 13 2002 169 172
17. F. Verschraegen, E. Gupta, and E. Loyer A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer Anticancer Drug 1999 10375 10383
18. H. Anderson, B. Lund, and F. Bach Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study J Clin Oncol 12 1994 1821 1826
19. E. EVokes, R. Rosenberg, and M. Jahanzeb Multicenter phase II study of weekly oral vinorelbine for stage IV non-small cell lung cancer J Clin Oncol 13 1995 637 644
20. R. Perez-Soler, F. Fossella, and B. Glisson Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy J Clin Oncol 14 1996 503 513
21. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999, 91, 66-72.
22. S. White, S. Cheeseman, and N. Thatcher Phase II study of oral topotecan in advanced non-small cell lung cancer Clin Cancer Res 6 2000 868 873